Guazzelli, Alice, Meysami, Parisa, Bakker, Emyr ORCID: 0000-0002-0091-1029, Demonacos, Constantinos, Giordano, Antonio, Krstic-Demonacos, Marija and Mutti, Luciano
(2019)
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.
International Journal of Molecular Sciences, 20
(2).
ISSN 1661-6596
Guazzelli, Alice, Meysami, Parisa, Bakker, Emyr ORCID: 0000-0002-0091-1029, Bonanni, Ezio, Demonacos, Constantinos, Krstic-Demonacos, Marija and Mutti, Luciano
(2019)
What can independent research for mesothelioma achieve to treat this orphan disease?
Expert Opinion on Investigational Drugs, 28
(8).
pp. 719-732.
ISSN 1354-3784
Tian, Kun, Bakker, Emyr ORCID: 0000-0002-0091-1029, Hussain, Michelle, Guazzelli, Alice, Alhebshi, Hasen, Meysami, Parisa, Demonacos, Constantinos, Schwartz, Jean-Marc, Mutti, Luciano et al
(2018)
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Journal of Translational Medicine, 16
.
p. 282.
Bakker, Emyr ORCID: 0000-0002-0091-1029, Guazzelli, Alice, Ashtiani, Firozeh, Demonacos, Constantinos, Krstic-Demonacos, Marija and Mutti, Luciano
(2017)
Immunotherapy advances for mesothelioma treatment.
Expert Review of Anticancer Therapy, 17
(9).
pp. 799-814.
ISSN 1473-7140
Guazzelli, Alice, Bakker, Emyr ORCID: 0000-0002-0091-1029, Tian, Kun, Demonacos, Constantinos, Krstic-Demonacos, Marija and Mutti, Luciano
(2017)
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Expert Opinion on Investigational Drugs, 26
(8).
pp. 933-944.
ISSN 1354-3784
Bakker, Emyr ORCID: 0000-0002-0091-1029, Guazzelli, Alice, Krstic-Demonacos, Marija, Sotgia, Federica, Lisanti, Michael and Mutti, Luciano
(2017)
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.
Expert Opinion on Orphan Drugs, 5
(6).
pp. 455-465.
Guazzelli, Alice, Bakker, Emyr ORCID: 0000-0002-0091-1029, Krstic-Demonacos, Marija, Lisanti, Michael P, Sotgia, Federica and Mutti, Luciano
(2017)
Anti-CTLA-4 therapy for malignant mesothelioma.
Immunotherapy, 9
(3).
pp. 273-280.
ISSN 1750-743X